持续吸入不同浓度氧气对新生大鼠肺血管内皮生长因子及其受体tuRNA表达的影响

目的 探讨持续吸入不同浓度氧气对新生大鼠肺血管内皮生长因子(VEGF)及其受体1(VEGFRl)和受体2(VEGFR2)mRNA表达的影响.方法 新生足月SD大鼠32只,随机分为对照组和实验组.实验组生后12 h开始持续吸入氧气,按不同的吸入氧浓度,将实验组又分为30%O2组、50%O2组和75%O2组.对照组吸入空气.每组8只.于实验开始后21 d处死实验大鼠,取出右肺下叶,RT-PCR技术检测VEGF、VEGFR1和VEGFR2 mRNA表达,根据2-△△CT的计算方法,实验组基因表达差异用实验组相对于对照组基因表达量的倍数表示.结果 与对照组相比,30%O2对新生大鼠肺VEGF及其受体mRNA表达无影响.75%O2组VEGF mRNA表达是对照组的0.48倍;50%O2组、75%O2组VEGFR1 mRNA分别为对照组的0.18倍和0.06倍;VEGFR2 mRNA分别为对照组的0.22倍和0.10倍,差异均有统计学意义(P<0.05).结论 长时间吸入低浓度氧对新生大鼠肺VEGF及其受体mRNA影响不明届,而持续吸入中等浓度及较高浓度氧可降低VEGF及其受体mRNA的表达.     

活血化瘀中药联合血管内皮生长因子基因转移促进股骨头坏死处新生血管形成的实验研究

目的:观察活血化瘀中药联合血管内皮生长因子(VEGF)基因转移对促进股骨头缺血坏死处新生血管形成情况。方法:日本大耳兔40只,随机分为对照组、模型组、中药组、基因组和综合组。治疗8周后采用免疫组织化学方法观察股骨头滑膜VEGF阳性细胞率及数字减影血管造影股骨头血管数目改变情况。结果:模型组VEGF阳性细胞表达率减低,与对照组、基因组、综合组比较,差异有显著性意义(P<0.01),与中药组比较,有统计学差异(P<0.05),综合组VEGF阳性细胞表达率较高,与中药组及基因组比较,有统计学差异(P<0.05)。血管数目:在A区,各组与模型组比较,均无统计学差异;在B区,各组较模型组血管数目均有增加,对照组、基因组、综合组与模型组比较,有统计学差异(P<0.05)。综合组与基因组比较有统计学差异(P<0.05),中药组虽然血管数目较模型组多,但是无统计学意义。结论:活血化瘀中药及VEGF基因转移均可促进股骨头缺血坏死处局部新生血管形成和侧支循环的建立,尤以活血化瘀中药联合基因疗法效果为好,为临床应用活血化瘀中药联合基因疗法治疗股骨头缺血性坏死提供实验依据。     

血管内皮生长因子与胸腔积液

血管内皮生长因子（VEGF）是目前已知活性最强、高度特异的血管生长因子。研究表明：VEGF可使血管通透性增加、渗出增多，在促进胸腔积液形成的过程中起重要作用。深入研究VEGF为进一步认识胸腔积液的发病机制及发展新的治疗策略提供了条件。     

血浆血管内皮细胞生长因子与肝细胞癌临床特征的相关性

目的通过检测肝细胞癌(HCC)患者肝动脉栓塞术前血浆血管内皮细胞生长因子(VEGF),考察VEGF表达与肿瘤大小、边界、门脉癌栓、远隔转移之间的相关性。方法收集介入治疗前HCC患者46例,VEGF定量检测采用双抗体夹心酶ABC ELISA法。根据血浆VEFG表达水平将患者分为阳性组(32例)和阴性组(14例),对肿瘤大小、边界、门脉癌栓、远隔转移情况进行组间对比。CT和DSA间接门脉造影获得的图像进行对比评估。结果VEGF阳性表达率69.56%(32/46),阴性表达率30.44%(14/46)。VEGF阳性组肿瘤直径>5cm者26例(81.25%),阴性组12例(85.75%),两组间无显著性差异(P>0.05)。CT片上阳性组肿瘤边界清楚15例(46.88%),阴性组边界清楚8例(57.14%),组间无显著性差异。阳性组门脉癌栓发生率62.50%(20/32),阴性组14.29%(2/14),两组间有极显著性差异(P<0.01)。阳性组远隔转移8例;阴性组无远隔转移,经检验P<0.05。结论血浆VEGF高表达可以提示门脉癌栓或远隔转移的存在,而与肿瘤大小、边界无关。血浆VEGF可能成为观察肿瘤门脉癌栓及远隔转移的指标。     

Vascular PET Prostheses Surface Modification with Cyclodextrin Coating: Development of a New Drug Delivery System

PURPOSE: Cyclodextrins (CDs) are torus shaped cyclic oligosaccharides with a hydrophobic internal cavity and a hydrophilic external surface. We performed and analysed an antibiotic binding on Dacron (polyethyleneterephtalate, PET) vascular grafts, previously coated with CDs based polymers. METHODS: The CDs coating process was based on the pad-dry-cure method patented in our laboratory. The Dacron prostheses were immersed into a solution containing a polycarboxylic acid, a cyclodextrin and a catalyst, and placed into a thermofixation oven before impregnation with an antibiotic solution (Vancomycin). Biocompatibility tests were performed with L132 human epithelial cells. The antibiotic release in an aqueous medium was assessed by batch type experiments using UV spectroscopy. RESULTS: Viability tests confirmed that the CDs polymers coating the Dacron fibers were not toxic towards L132 cell. Cell proliferation was similar on coated and uncoated grafts. A linear release of Vancomycin was observed over 50 days. CONCLUSION: Our results demonstrate the feasibility of coating CDs onto vascular Dacron grafts. Biological tests show no toxicity of the different cyclodextrins coated. A linear release of antibiotics was depicted over 50 days, demonstrating that cyclodextrin grafting was an efficient drug delivery system.     

Vascular endothelial growth factor and its receptor expression during the process of fracture healing

Objective： To study the expression regularity of vascular endothelial growth factor （VEGF） during the process of fracture healing, and the type of VEGF receptor expressed in the vascular endothelial cells of the fracture site.
Methods： The fracture model was made in the middle part of left radius in 35 rabbits. The specimens from the fracture site were harvested at 8, 24, 72 hours and 1, 3, 5, 8 weeks, and then fixed, decalcified, and sectioned frozenly to detect the expression of VEGF and its receptor at the fracture site by in situ hybridization and immunochemical assays.
Results： VEGF mRNA and VEGF expression was detected in many kinds of cells at the fracture site during 8 hours to 8 weeks after fracture. Fltl receptor of VEGF was found in the vascular endothelial cells at the fracture site during 8 hours to 8 weeks after fracture, and strong expression of flkl receptor was detected from 3 days to 3 weeks after fracture.
Conclusions： The expression of VEGF and fltl receptor appears during the whole course of fracture healing, especially from 1 to 3 weeks. Flkl receptor is highly expressed in a definite period after fracture. VEGF is proved to be involved in the vascular reconstruction and fracture healing.     

子宫内膜异位症患者血清及腹腔液中血小板衍生生长因子、血管细胞粘附分子水平的变化及其意义

目的通过检测子宫内膜异位症(EMs)患者血清及腹腔液中血小板衍生生长因子(PDGF)、血管细胞粘附分子-(VCAM-1)浓度,探讨PDGF和VCAM-1在EMs发病中的作用。方法选取手术后病理证实为EMs的40例患者为EMs组,其中I~II期17例,III~IV23例;非EMs组20例作为对照组。应用酶联免疫吸附法(ELISA)检测血清及腹腔液中PDGF和VCAM-1水平。结果EMs组血清及腹腔液中PDGF、VCAM-1水平均明显高于对照组(P<0.01)。随EMs期别的增加,其血清和腹腔液中PDGF、VCAM-1含量呈上升趋势;EMsIII~IV期水平显著高于I~II期(P<0.05)。EMs患者PDGF与VCAM-1呈正相关性(P<0.05)。结论EMs患者PDGF、VCAM-1表达水平升高,在EMs的发生发展中具有重要作用。     

重组人生长激素对荷人胃癌裸鼠移植瘤血管内皮生长因子表达的影响

目的研究重组人生长激素（rhGH）对生长激素受体（GHR）不同表达状态裸鼠人胃癌移植瘤生长及血管内皮生长因子（VEGF）表达的影响。方法采用免疫细胞化学染色法筛选出GHR阳性和阴性表达的细胞株各1株，分别接种于24只裸鼠皮下。将两种细胞接种裸鼠均随机分为对照组（0．9％NaCl，0．2ml／d）、低剂量rhGH组（0．5U·kg^-1·d^-1，0．2ml／d）和高剂量rhGH组（2．5U·kg^-1·d^-1，0．2mL／d）3组，每组8只，各组均连续给药14d，观察并记录裸鼠体重和肿瘤体积变化；采用酶联免疫吸附法测定各组裸鼠血清VEGF含量，免疫组织化学方法检测胃癌组织中VEGF蛋白表达，RT-PCR方法检测胃癌组织VEGFmRNA水平变化。结果筛选出GHR阳性表达的人胃癌细胞株SGC-7901和阴性表达的MKN-45。对于GHR^＋SGC-7901接种裸鼠，rhGH给药组皮下移植瘤体积较对照组增大（P〈0．05），且高剂量rhGH组促增长效应最为显著（P〈0．05），3组间体重差异无统计学意义（P〉0．05）；高剂量rhGH组的血清VEGF浓度为（252．94±15．32）ng／L，明显高于对照组的（49．94±5．73）ng／L和低剂量rhGH组的（167．60±9．54）ng／L（P〈0．05）；对照组VEGF表达为中度阳性，rhGH给药组呈强阳性；高剂量rhGH组肿瘤组织中VEGFmRNA相对表达量为0．6470±0．0447，明显高于对照组的0．3230±0．0258和低剂量rhGH组的0．4120±0．0351（P〈0．05）。对于GHR—MKN-45接种裸鼠，rhGH给药组体重明显大于对照组（P〈0．05）；肿瘤体积大小、血清VEGF水平、肿瘤组织VEGF蛋白及mRNA表达，3组间差异均无统计学意义（P〉0．05）。结论rhGH能促进GHR阳性表达的SGC-7901移植瘤生长，并促进VEGF表达增高；对于GHR阴性的MKN-45移植瘤，则没有表现出明显的促肿瘤生长及促VEGF表达效应。GHR存在可能是rhGH影响VEGF分泌的关键靶点。     

Expression and distribution of vascular endothelial growth factor protein in human brain tumors

Marked neovascularization is a hallmark of many neoplasms in the nervous system. Recent reports indicate that the endothelial mitogen vascular endothelial growth factor (VEGF) may play a critical role in the regulation of vascular endothelial proliferation in malignant gliomas. Using novel monoclonal antibodies to the VEGF polypeptide we have determined the expression and cellular distribution of VEGF protein in a representative series of 171 human central nervous system (CNS) tumors by immunohistochemistry and immunoblotting. In agreement with previous in situ hybridization data, 19 out of 20 glioblastomas (95%) showed immunoreactivity for VEGF, whereas both the percentage of immunoreactive tumors and the extent of immunoreactivity for VEGF were significantly lower in astrocytomas. Of the pilocytic astrocytomas (WHO grade I) 44% were immunoreactive for VEGF, but we observed several cases with pronounced vascular proliferates in the absence of VEGF. In ependymomas, meningiomas, hemangioblastomas, and primitive neuroectodermal tumors, there was no correlation between VEGF expression, vascular endothelial proliferation and the grade of malignancy. Oligodendrogliomas and the oligodendroglial component of mixed gliomas lacked immunoreactive VEGF, indicating that endothelial growth factors other than VEGF may regulate tumor angiogenesis in these neoplasms. Western blot analysis showed a predominant VEGF protein species of 23 kDa and confirmed the immunohistochemical data in all cases. Our findings demonstrate that VEGF is expressed in a wide spectrum of brain tumors in which it may induce neovascularization. However, other angiogenic factors also appear to contribute to the vascularization of CNS neoplasms. Received: 18 April 1996 / Revised, accepted: 20 August 1996     

Vascular Access for Therapeutic Plasma Exchange

Abstract: Adequate venous access is an essential component of therapeutic plasma exchange (TPEX). The simplest kind of venous access is venipuncture of antecubital veins, but this technique may be limited by venous size or scarring following the procedure, requiring the placement of a specialized vascular access device (VAD). VADs provide reliable central venous access and may remain in place for several weeks or months, depending on the VAD and the venous site chosen. Their use, however, is potentially limited by the risk of complications. We discuss indications for insertion, choice of catheter and access site, and complications of VAD placement for TPEX.